Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
ECDC estimate: Around 9 million Europeans are affected by chronic hepatitis B or C

An estimated 4.7 million Europeans are living with chronic hepatitis B and almost 4 million with chronic hepatitis C infection. But large numbers of them are not aware of their infection as they have not yet been diagnosed. On of World Hepatitis Day, ECDC Director Andrea Ammon highlights the need for Europe to scale-up coverage of testing, prevention interventions and linkage to suitable treatment services to achieve the target of eliminating viral hepatitis by 2030.

Published
2 hours ago
From
Eurekalert Inf Dis
Glecaprevir/pibrentasvir is effective for people with HIV/HCV co-infection

AbbVie's new pangenotypic regimen combining glecaprevir and pibrentasvir cured almost all HIV-positive people with hepatitis C co-infection in the EXPEDITION-2 study, according to a presentation on Monday

Published
26 July 2017
By
Liz Highleyman
Hepatitis C treatment is effective and feasible in Africa

Treatment for hepatitis C in sub-Saharan Africa can produce cure rates as high as those seen in industrialised countries, with high adherence and minimal side-effects, according to

Published
25 July 2017
By
Liz Highleyman
WHO prequalifies first generic hepatitis C medicine and first HIV self-test

WHO today prequalified the first generic version of sofosbuvir, a critical medicine for the treatment of hepatitis C. The development could expand access to treatment by increasing the number of quality-assured generic medicines on the market. Sofosbuvir, 400 mg tablet, is manufactured by Mylan Laboratories Ltd., India.

Published
22 July 2017
From
World Health Organization
US regulator approves Gilead's Vosevi combo pill for hepatitis C retreatment

On 18 July the US Food and Drug Administration (FDA) approved Gilead Sciences' Vosevi, a new once-daily combination pill containing sofosbuvir, velpatasvir, and voxilaprevir. Vosevi

Published
19 July 2017
By
Liz Highleyman
The 2017 Pipeline Report

Treatment Action Group (TAG) announces the launch of its annual research and development landscape analysis: The Pipeline Report: Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development.

Published
19 July 2017
From
Treatment Action Group
Targeting MSM with HIV: Treatment as Prevention in the Netherlands

As part of Dutch HIV guidelines, all individuals with HIV are screened for hepatitis C. Anne Boerekamps, MD, of Erasmus University Medical Center in Rotterdam, the Netherlands, spoke with HCV Next about the Dutch approach, the relevant data, and other topics associated with screening and treating MSM.

Published
18 July 2017
From
Healio Hepatology
Liver Cancer is What Killed Jailed Chinese Dissident Lu Xiaobo

The dissident’s plight has come under a global spotlight amid allegations from his supporters that Liu fell gravely ill because his cancer was not detected or treated while he was in prison. Prison authorities said Liu, who also had a history with the hepatitis B virus (HBV) received monthly check-ups and had “no abnormal conditions” before the liver cancer diagnosis.

Published
17 July 2017
From
Hepmag
Non-alcoholic fatty liver disease common in people living with HIV – metabolic disorders are key risk factors

Over a third of people with HIV have non-alcoholic fatty liver disease (NAFLD) in the absence of hepatitis B or C, according to the results

Published
12 July 2017
By
Michael Carter
Contaminated blood scandal: Theresa May orders inquiry

Inquiry to look into deaths of 2,400 people after thousands were infected with hepatitis C and HIV in 1970s and 80s.

Published
11 July 2017
From
The Guardian
← First12345...224Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.